Transient transfection at large scale for clinical AAV9 vector manufacturing
AAV9 production in adherent HEK293 cells was scaled from the pilot iCELLis® Nano bioreactor to the large scale iCELLis 500 bioreactor (200 m2 and 333 m2 surface area). A HEK293 cell seed train was utilized, using the Xpansion® 200 bioreactor. Media components were evaluated and replenished as needed throughout the run using the perfusion process of the iCELLis bioreactor. Following a production phase, >1016 vector genomes were isolated from crude harvest of the bioreactor.
Speaker
Rachel Legmann
Director, Technical Consultancy - Gene Therapy and Viral Vectors
Pall Biotech, USA
Rachel has more than 20 years of experience in the field of scalable biologics and gene therapy manufacturing of therapeutic products, viral vector and proteins for gene therapy and biologics. She completed her Ph.D. in Food Engineering and Biotechnology at the Technion-Israel Institute of Technology, Israel.
Rachel joined Pall in 2014 and currently serves as a process development services senior lab manager in charge of upstream and downstream process development, scale-up, and manufacturing support activities for the gene therapy and biologics markets.
Prior to joining Pall, Rachel held several scientific and leadership roles at Microbiology & Molecular Genetics department at Harvard Medical School, SBH Sciences, Seahorse Biosciences, and Goodwin Biotechnology.
Transient transfection at large scale for clinical AAV9 vector manufacturing
Learn about scalable, single-use solutions for purification of viral vectors
Watch Todd Sanderson’s video presented during ICST 2020 Virtual event.
Biotech | Pall Corporation 웨비나 시리즈
¡Todo sobre los ensayos de validaciones para cumplir con los máximos estándares regulatorios!
Hablaremos sobre puntos cruciales de los servicios de validación, incluyendo:
1. Necesidad de validación
2. Cómo se realizan los ensayos de validación
3. Análisis de riesgo: re uso de filtros y toma de decisión en ensayos a realizar
4. Servicio de Validación Pall: documentación requerida para iniciar una cotización
¡No pierdas esta segunda oportunidad!